Document is current
Any future updates will be listed below
-
Authors
Cuesta-Marti, Cristina https://orcid.org/0000-0001-5801-9394
Ponce-España, Eduardo https://orcid.org/0000-0001-6197-0041
Uhlig, Friederike https://orcid.org/0000-0001-7441-1951
Stoltenborg, Iris
Wasiewska, Luiza A.
Kareem, Lamiah
Hedayatpour, Dara
Olavarría-Ramírez, Loreto
Rosell-Cardona, Cristina https://orcid.org/0000-0003-3627-9413
Bastiaanssen, Thomaz. F. S. https://orcid.org/0000-0001-6891-734X
Tofani, Gabriel. S. S. https://orcid.org/0009-0008-5140-1628
Valderrama, Benjamin
Vlckova, Klara
Dickson, Suzanne L.
Lavelle, Aonghus
Stanton, Catherine https://orcid.org/0000-0002-6724-7011
Ross, R. Paul https://orcid.org/0000-0003-4876-8839
Cryan, John F. https://orcid.org/0000-0001-5887-2723
Dinan, Timothy G. https://orcid.org/0000-0002-2316-7220
Clarke, Gerard https://orcid.org/0000-0001-9771-3979
O’Mahony, Siobhain M.
Schellekens, Harriët https://orcid.org/0000-0002-6065-3797
-
Funding
Funding for this research was provided by:
Universidad de Sevilla (VI PPIT-US)
Science Foundation Ireland (22/PATH-S/10882)
- License Information
-
More Information
Article History
Received: 2 May 2025
Accepted: 20 January 2026
First Online: 24 February 2026
Competing interests
: The authors declare no competing non-financial interests. The following competing financial interests are declared: G.C. received honoraria from Janssen, Probi, Ingelheim Boehringer and Apsen, as an invited speaker, and research funding from Pharmavite, Reckitt, Tate & Lyle PLC, Nestle, Fonterra and is or has been a paid consultant for Heel Pharmaceuticals, Bayer Healthcare, Yakult and Zentiva; H.S. has obtained research funding from Pharmavite, Cremo, Tate & Lyle PLC, Pepsico, and Fonterra. This support did not influence or constrain the study design, data analysis, collection, data interpretation, writing or overall content of this manuscript. H.S., T.D., J.F.C., and C.S. are inventors on a patent for other findings previously identified with the in-house bacterial strain used in the present work (filed and pending, EP17187989.3, entitled: “ Bifidobacterium longum APC1472 for treating obesity and weight management”). The remaining authors declare no competing interests.
